NKGN
$1.82
NKGN info-6.67%ย โ€ข 24 H
Dividend Yield:-
Global Rank#27115
Market Cap$59.34M
YTD Performance-33.82%
P/E-2.22
Revenue$77.00K
Change 7d-3.19%
SP500 BenchmarkUnderperform
P/S770.62
Earnings-$26.75M

(NKGN) Stock Overview

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

NKGN Stock Information

SymbolNKGN
Address
3001 Daimler StreetSanta Ana, CA 92705United States
Founded-
Trading hours-
Websitehttps://nkgenbiotech.com
Country๐Ÿ‡บ๐Ÿ‡ธ United States
Phone Number949-396-6830

(NKGN) Price Chart

-
Value:-

Overview: Key Details and Summary

Stock data
2022
Change
Price
$1.82
N/A
Market Cap
$59.34M
N/A
Shares Outstanding
32.60M
0.00%
Employees
0
N/A
Shareholder Equity
1.56M
-104.11%
Valuation
2022
Change
P/E Ratio
-2.22
N/A
P/S Ratio
770.62
N/A
P/B Ratio
37.96
N/A
Growth
2022
Change
Return on Equity
-17.1171
N/A
Earnings
2022
Change
Revenue
$77.00K
N/A
Earnings
-$26.75M
N/A
EPS
-0.8206
N/A
Earnings Yield
-0.4509
N/A
Gross Margin
0.7662
N/A
Operating Margin
-316.18
N/A
Net income margin
-347.45
N/A
Financial Strength
2022
Change
Total Assets
$16.33M
N/A
Total Debt
$12.03M
N/A
Cash on Hand
$117.00K
N/A
Debt to Equity
$9.45
-740.59%
Cash to Debt
0.0097
43.96%
Current Ratio
0.0237
116.26%
ยฉ 2024 TopStocks.org
Facebook Icon
Twitter Icon
Linkedin Icon